- Home
- SLS
as 07-26-2024 4:00pm EST
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 68.2M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 729.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $1.90 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest SELLAS Life Sciences Group Inc. News
SLS Breaking Stock News: Dive into SLS Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation
GlobeNewswire
10 days ago
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
MT Newswires
18 days ago
Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation
GlobeNewswire
18 days ago
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
GlobeNewswire
a month ago
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
GlobeNewswire
a month ago
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
GlobeNewswire
2 months ago
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
Simply Wall St.
2 months ago
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
Compare SLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLS SELLAS Life Sciences Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.